Orforglipron / Foundayo begins here with a US FDA medicine identity.
Each answer stays attached to the compound identity and destination records. This is a verification guide, not medical or legal advice, a seller recommendation, or proof of availability.
Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in India. Verify the exact local records below.
Resolve the exact identity of Orforglipron / Foundayo through Current FOUNDAYO prescribing information from National Library of Medicine, DailyMed. Then search Approved new drugs from Central Drugs Standard Control Organization for the destination product record and Drug and quality alerts from Central Drugs Standard Control Organization for the seller, establishment, or supply route in India. A match in one record does not replace the other two checks.
No. A page using the name Orforglipron / Foundayo, local currency, a domestic delivery claim, or a familiar package image is only a lead. FOUNDAYO is an FDA-approved US oral medicine containing the non-peptide small molecule orforglipron. That US approval does not establish authorization, launch, prescription access, market presence, supply, or seller authority in another country, and it does not authenticate a same-name research or imported product. For India, the exact product, presentation, seller identity, current record status, and claimed supply route must resolve through the official sources on this page.
Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in India. Verify the exact local records below.
Primary identity source: Current FOUNDAYO prescribing information / National Library of Medicine, DailyMed ↗A credible result must keep these separate. The official links answer different questions and should be checked in sequence.
Current FOUNDAYO prescribing information is maintained by National Library of Medicine, DailyMed. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Open Current FOUNDAYO prescribing information ↗Approved new drugs is maintained by Central Drugs Standard Control Organization. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Open Approved new drugs ↗Drug and quality alerts is maintained by Central Drugs Standard Control Organization. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.
Open Drug and quality alerts ↗India's medicine oversight combines central responsibilities with state licensing and enforcement. CDSCO publishes new-drug approvals and quality or spurious-product alerts, but neither list by itself verifies a clinic, pharmacy, imported research listing, or local seller claim.
The country guide supplies the local verification sequence. It does not convert an online listing into an authorized product or verified seller.
Search CDSCO's approved new-drug records for the exact name and approval period. Do not treat a foreign authorization, sponsor announcement, or ingredient match as an Indian approval entry.
Check CDSCO alerts for not-of-standard-quality and spurious batches. An approval record and a later batch alert answer different questions and both may matter.
Pharmacy and sale permissions may depend on the relevant State Drug Control authority, so match the business and jurisdiction instead of assuming a central product entry verifies the seller.
Open the live record and confirm its current status. A linked source begins the verification process; it does not mean Peptide Local authenticated a product or seller.